GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Shiller PE Ratio

Otonomy (Otonomy) Shiller PE Ratio : (As of May. 06, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Otonomy Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Otonomy Shiller PE Ratio Historical Data

The historical data trend for Otonomy's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otonomy Shiller PE Ratio Chart

Otonomy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Otonomy Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Otonomy's Shiller PE Ratio

For the Biotechnology subindustry, Otonomy's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Otonomy's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Otonomy's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Otonomy's Shiller PE Ratio falls into.



Otonomy Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Otonomy's E10 for the quarter that ended in Sep. 2022 is calculated as:

For example, Otonomy's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.18/125.2265*125.2265
=-0.180

Current CPI (Sep. 2022) = 125.2265.

Otonomy Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 0.000 96.871 0.000
201303 -0.234 98.209 -0.298
201306 -0.337 98.518 -0.428
201309 -0.503 98.790 -0.638
201312 -0.677 98.326 -0.862
201403 -0.944 99.695 -1.186
201406 -0.528 100.560 -0.658
201409 -1.230 100.428 -1.534
201412 -0.460 99.070 -0.581
201503 -0.520 99.621 -0.654
201506 -0.520 100.684 -0.647
201509 -0.660 100.392 -0.823
201512 -0.870 99.792 -1.092
201603 -0.910 100.470 -1.134
201606 -0.980 101.688 -1.207
201609 -0.910 101.861 -1.119
201612 -0.880 101.863 -1.082
201703 -0.890 102.862 -1.084
201706 -0.770 103.349 -0.933
201709 -0.690 104.136 -0.830
201712 -0.620 104.011 -0.746
201803 -0.370 105.290 -0.440
201806 -0.440 106.317 -0.518
201809 -0.410 106.507 -0.482
201812 -0.420 105.998 -0.496
201903 -0.390 107.251 -0.455
201906 -0.380 108.070 -0.440
201909 -0.330 108.329 -0.381
201912 -0.360 108.420 -0.416
202003 -0.380 108.902 -0.437
202006 -0.370 108.767 -0.426
202009 -0.220 109.815 -0.251
202012 -0.200 109.897 -0.228
202103 -0.230 111.754 -0.258
202106 -0.190 114.631 -0.208
202109 -0.190 115.734 -0.206
202112 -0.200 117.630 -0.213
202203 -0.200 121.301 -0.206
202206 -0.190 125.017 -0.190
202209 -0.180 125.227 -0.180

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Otonomy  (OTCPK:OTIC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Otonomy Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Otonomy's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Otonomy (Otonomy) Business Description

Traded in Other Exchanges
N/A
Address
4796 Executive Drive, San Diego, CA, USA, 92121
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
Executives
Hogan H Michael Iii director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster officer: Chief Scientific Officer 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii officer: Chief Technical Officer 1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer officer: CFO/Ch. Business Offcr & Sec. C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber director, officer: President & CEO C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer director
Eric J Loumeau officer: GC & Chief Compliance Officer C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop officer: Chief Scientific Officer C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel officer: Chief Scientific Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong director C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022